Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab

BACKGROUND: Antiangiogenic therapy with bevacizumab has failed to provide substantial gains in overall survival. Epithelial membrane protein 2 (EMP2) is a cell surface protein that has been previously shown to be expressed in glioblastoma, correlate with poor survival, and regulate neoangiogenesis i...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Kunal S, Kejriwal, Sameer, Thammachantha, Samasuk, Duong, Courtney, Murillo, Adrian, Gordon, Lynn K, Cloughesy, Timothy F, Liau, Linda, Yong, William, Yang, Isaac, Wadehra, Madhuri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542982/
https://www.ncbi.nlm.nih.gov/pubmed/33063013
http://dx.doi.org/10.1093/noajnl/vdaa112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542982/
https://www.ncbi.nlm.nih.gov/pubmed/33063013
http://dx.doi.org/10.1093/noajnl/vdaa112

Ejemplares similares